Johnson & Johnson acquires Halda Therapeutics for $3.05bn

Johnson & Johnson (J&J) has completed its acquisition of Halda Therapeutics, a clinical-stage biotechnology company, for $3.05bn successful cash.

This determination brings Halda’s Regulated Induced Proximity Targeting Chimera (RIPTAC) level to J&J’s oncology portfolio, supporting the improvement of oral, targeted therapies for respective coagulated tumours, including prostate cancer.

The acquisition includes HLD-0915, a clinical-stage, once-daily oral therapy for prostate cancer. This therapy utilises the RIPTAC level for precision targeting of crab cells, aiming to code absorption mechanisms.

Additionally, the woody adds early-stage candidates for breast, lung, and different tumour types, utilizing RIPTAC technology, to J&J’s pipeline.

The institution indicated that this level could perchance alteration the improvement of further targeted therapies beyond oncology.

With the woody closing successful 2025, J&J anticipates net dilution successful the 4th fourth of 2025 and into 2026.

The full interaction connected adjusted net per stock is expected to beryllium astir $0.20, divided arsenic betwixt 2025 and 2026, reflecting charges related to Halda worker equity, financing, and integration costs.

J&J innovative medicine worldwide president and enforcement vice president Jennifer Taubert said: “This strategical milestone underscores our committedness to redefining crab attraction with breakthrough subject and transformative medicines.

“We are excited to formally invited the talented Halda squad to J&J and look guardant to moving unneurotic to execute our shared extremity of eliminating cancer.”

J&J innovative medicine R&D enforcement vice-president John Reed said: “Now that we person finalised this acquisition, we volition absorption connected advancing the imaginable of this promising pipeline of caller merchandise candidates and harnessing the almighty RIPTAC level to observe much molecules successful oncology and beyond.”

In November 2025, J&J signed a definitive statement for the acquisition of Halda.

"Johnson & Johnson acquires Halda Therapeutics for $3.05bn" was primitively created and published by Pharmaceutical Technology, a GlobalData owned brand.

The accusation connected this tract has been included successful bully religion for wide informational purposes only. It is not intended to magnitude to proposal connected which you should rely, and we springiness nary representation, warranty oregon guarantee, whether explicit oregon implied arsenic to its accuracy oregon completeness. You indispensable get nonrecreational oregon specializer proposal earlier taking, oregon refraining from, immoderate enactment connected the ground of the contented connected our site.